Inomax
Lung Disease
MallinckrodtPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
9 Active assets in the Lung Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Interferon Gamma-1B InterMune | Phase 3 | B |
Azathioprine InterMune | Phase 3 | B |
Imatinib Daniels, Craig E., M.D. | Phase 2/3 | B |
Fludarabine Pfizer | Phase 2 | CCC |
Calaspargase Pegol Pfizer | Phase 2 | CCC |
View all 12 →
Same molecule, other indications
Inomax is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →